Fig. 3. Possible involvement of GLP-1 signaling in NASH.

The benefits of GLP-1 mimetics include: (i) Alleviation of insulin resistance via insulinotropic action and insulin signal enhancement, both in the liver and in peripheral tissues; (ii) Suppression of DNL, triglycerides synthesis and subsequent VLDL particle production in the liver; (iii) Balancing mitochondria biogenesis and function, decreasing ROS formation and increasing hepatic anti-oxidant capacity; (iv) Participating in Ca²⁺ homeostasis and reducing factors associated with ER stress; (v) Anti-inflammatory and anti-fibrosis actions; and (vi) Restoring microbiota dysbiosis and reversing the state of GLP-1 resistance.